Able 0 4 0 4 O
and 5 8 5 8 O
willing 9 16 9 16 O
to 17 19 17 19 O
complete 20 28 20 28 O
the 29 32 29 32 O
Skindex16 33 42 33 42 O
and 43 46 43 46 O
Skin 47 51 47 51 O
Cancer 52 58 52 58 O
Index 59 64 59 64 O
( 65 66 65 66 O
must 66 70 66 70 O
be 71 73 71 73 O
able 74 78 74 78 O
to 79 81 79 81 O
speak 82 87 82 87 B-language_fluency
English 88 95 88 95 I-language_fluency
) 95 96 95 96 O

BCC 0 3 97 100 B-cancer
/ 3 4 100 101 O
SCC 4 7 101 104 B-cancer
in 8 10 105 107 O
area 11 15 108 112 O
prone 16 21 113 118 O
to 22 24 119 121 O
trauma 25 31 122 128 B-chronic_disease
( 32 33 129 130 O
including 33 42 130 139 O
, 42 43 139 140 O
but 44 47 141 144 O
not 48 51 145 148 O
limited 52 59 149 156 O
to 60 62 157 159 O
the 63 66 160 163 O
skin 67 71 164 168 O
overlying 72 81 169 178 O
the 82 85 179 182 O
tibia 86 91 183 188 O
, 91 92 188 189 O
dorsum 93 99 190 196 O
of 100 102 197 199 O
hands 103 108 200 205 O
and 109 112 206 209 O
elbow 113 118 210 215 O
) 118 119 215 216 O

BCC 0 3 217 220 B-cancer
/ 3 4 220 221 O
SCC 4 7 221 224 B-cancer
in 8 10 225 227 O
area 11 15 228 232 O
with 16 20 233 237 O
compromised 21 32 238 249 O
lymphatic 33 42 250 259 O
drainage 43 51 260 268 O
or 52 54 269 271 O
vascular 55 63 272 280 O
supply 64 70 281 287 O

BCC 0 3 288 291 O
/ 3 4 291 292 O
SCC 4 7 292 295 O
in 8 10 296 298 O
region 11 17 299 305 O
adjacent 18 26 306 314 O
to 27 29 315 317 O
or 30 32 318 320 O
overlapping 33 44 321 332 O
with 45 49 333 337 O
region 50 56 338 344 O
of 57 59 345 347 O
prior 60 65 348 353 O
radiotherapy 66 78 354 366 B-treatment

BCC 0 3 367 370 B-cancer
/ 3 4 370 371 O
SCC 4 7 371 374 B-cancer
on 8 10 375 377 O
irregular 11 20 378 387 O
surface 21 28 388 395 O
( 29 30 396 397 O
ie 30 32 397 399 O
, 32 33 399 400 O
target 34 40 401 407 O
area 41 45 408 412 O
not 46 49 413 416 O
flat 50 54 417 421 O
) 54 55 421 422 O

BCC 0 3 423 426 B-cancer
/ 3 4 426 427 I-cancer
SCC 4 7 427 430 I-cancer
that 8 12 431 435 O
was 13 16 436 439 O
previously 17 27 440 450 O
treated 28 35 451 458 O
( 36 37 459 460 O
ie 37 39 460 462 O
, 39 40 462 463 O
recurrent 41 50 464 473 O
BCC 51 54 474 477 O
/ 54 55 477 478 O
SCC 55 58 478 481 O
) 58 59 481 482 O

BCC 0 3 483 486 B-cancer
/ 3 4 486 487 I-cancer
SCC 4 7 487 490 I-cancer
within 8 14 491 497 O
3 15 16 498 499 B-upper_bound
cm 17 19 500 502 I-upper_bound
of 20 22 503 505 O
another 23 30 506 513 O
treated 31 38 514 521 O
or 39 41 522 524 O
untreated 42 51 525 534 O
BCC 52 55 535 538 O
/ 55 56 538 539 O
SCC 56 59 539 542 O

Basal 0 5 543 548 B-cancer
cell 6 10 549 553 I-cancer
carcinoma 11 20 554 563 I-cancer
with 21 25 564 568 I-cancer
morpheaform 26 37 569 580 I-cancer
, 37 38 580 581 O
sclerosing 39 49 582 592 O
, 49 50 592 593 O
mixed 51 56 594 599 O
, 56 57 599 600 O
infiltrative 58 70 601 613 O
or 71 73 614 616 O
micronodular 74 86 617 629 B-clinical_variable
features 87 95 630 638 I-clinical_variable
must 96 100 639 643 O
be 101 103 644 646 O
≤1 104 106 647 649 O
cm 107 109 650 652 I-upper_bound

Collagen 0 8 653 661 B-chronic_disease
vascular 9 17 662 670 I-chronic_disease
disease 18 25 671 678 I-chronic_disease
( 26 27 679 680 O
lupus 27 32 680 685 B-chronic_disease
, 32 33 685 686 O
scleroderma 34 45 687 698 B-chronic_disease
, 45 46 698 699 O
rheumatoid 47 57 700 710 B-chronic_disease
arthritis 58 67 711 720 I-chronic_disease
) 67 68 720 721 O

Diabetes 0 8 722 730 B-chronic_disease
that 9 13 731 735 O
is 14 16 736 738 O
poorly 17 23 739 745 O
controlled 24 34 746 756 O

Eastern 0 7 757 764 B-clinical_variable
Cooperative 8 19 765 776 I-clinical_variable
Oncology 20 28 777 785 I-clinical_variable
Group 29 34 786 791 I-clinical_variable
( 35 36 792 793 I-clinical_variable
ECOG 36 40 793 797 I-clinical_variable
) 40 41 797 798 I-clinical_variable
performance 42 53 799 810 I-clinical_variable
status 54 60 811 817 I-clinical_variable
of 61 63 818 820 O
0 64 65 821 822 B-lower_bound
- 65 66 822 823 O
3 66 67 823 824 B-upper_bound
( 68 69 825 826 O
Appendix 69 77 826 834 O
C 78 79 835 836 O
) 79 80 836 837 O

Genetic 0 7 838 845 B-chronic_disease
disorder 8 16 846 854 I-chronic_disease
predisposing 17 29 855 867 O
patient 30 37 868 875 O
to 38 40 876 878 O
skin 41 45 879 883 B-cancer
cancers 46 53 884 891 I-cancer
or 54 56 892 894 O
radiation 57 66 895 904 B-allergy_name
sensitivity 67 78 905 916 I-allergy_name
( 79 80 917 918 O
basal 80 85 918 923 B-chronic_disease
cell 86 90 924 928 I-chronic_disease
nevus 91 96 929 934 I-chronic_disease
syndrome 97 105 935 943 I-chronic_disease
, 105 106 943 944 O
xeroderma 107 116 945 954 B-chronic_disease
pigmentosum 117 128 955 966 I-chronic_disease
, 128 129 966 967 O
ataxia 130 136 968 974 B-chronic_disease
telangiectasia 137 151 975 989 I-chronic_disease
mutans 152 158 990 996 I-chronic_disease
) 158 159 996 997 O

Histopathologic 0 15 998 1013 O
diagnosis 16 25 1014 1023 O
of 26 28 1024 1026 O
basal 29 34 1027 1032 B-cancer
or 35 37 1033 1035 O
squamous 38 46 1036 1044 B-cancer
cell 47 51 1045 1049 I-cancer
carcinoma 52 61 1050 1059 I-cancer

Men 0 3 1060 1063 B-gender

Receipt 0 7 1064 1071 O
of 8 10 1072 1074 O
drug 11 15 1075 1079 O
that 16 20 1080 1084 O
will 21 25 1085 1089 O
affect 26 32 1090 1096 O
biologic 33 41 1097 1105 O
response 42 50 1106 1114 O
to 51 53 1115 1117 O
radiation 54 63 1118 1127 B-treatment
( 64 65 1128 1129 O
radiosensitizer 65 80 1129 1144 B-treatment
or 81 83 1145 1147 O
radioprotector 84 98 1148 1162 B-treatment
) 98 99 1162 1163 O

women 0 5 1164 1169 B-gender

≥ 0 1 1170 1171 O
60 2 4 1172 1174 B-lower_bound
years 5 10 1175 1180 I-lower_bound
old 11 14 1181 1184 O
with 15 19 1185 1189 O
estimated 20 29 1190 1199 O
life 30 34 1200 1204 B-clinical_variable
expectancy 35 45 1205 1215 I-clinical_variable
of 46 48 1216 1218 O
≥ 49 50 1219 1220 O
5 51 52 1221 1222 B-lower_bound
years 53 58 1223 1228 I-lower_bound

